股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | ...

Group 1 - The Hang Seng Index rose by 1.02%, gaining 267 points to close at 26,427 points, while the Hang Seng Tech Index increased by 1.48% [1] - Baidu Group-SW (09888) surged over 5% as its recent project "萝卜快跑" launched in Switzerland, with institutions shifting valuation logic towards AI integration [1] - Copper prices approached highs due to positive sentiment from US-China tariff negotiations, leading to a collective rise in copper stocks, with Luoyang Molybdenum (03993) up 4.5% and Jiangxi Copper (00358) up 4.6% [1] Group 2 - Bitcoin surpassed $115,000, increasing by 3.35% in a day, which positively impacted cryptocurrency-related stocks, with New Fire Technology Holdings (01611) rising over 11% and Boya Interactive (00434) up 5.5% [1] - Chongqing Bank (01963) saw its stock rise over 4%, reporting over 10% growth in both revenue and net profit for the first three quarters, and plans to distribute cash dividends of approximately 585 million yuan [1] - Meitu Inc. (01357) increased over 7%, with its three core apps achieving record revenue growth year-on-year in September, benefiting from the overseas holiday season [1] Group 3 - Conant Optical (02276) rose over 5% as Alibaba launched its self-developed Quark AI glasses, with the company being the exclusive lens supplier [1] - Boleton (01333) increased by 4%, as the electric mining sector moves towards a market-driven phase, highlighting the company's product performance advantages [1] - Aux Electric (02580) surged over 7% after the board approved a three-year dividend payout plan, with stable domestic sales [1] Group 4 - Tiangong International (00826) rose over 6%, positioning itself in the scarce core materials sector, with significant growth potential in titanium alloys and nuclear fusion materials [1] - Qiming Medical-B (02500) increased over 12% after completing all clinical enrollments for the CARDIOVALVE TTVR confirmatory clinical study [1] - GAC Group (02238) fell by 2.6%, reporting a loss of approximately 4.312 billion yuan in the first three quarters, marking a shift from profit to loss year-on-year [1] - Xiaomi Group-W (01810) declined by 2.7%, with Citigroup predicting its third-quarter performance may slightly underperform expectations [1]

Group 1 - Hong Kong's Hang Seng Index rose by 1.02%, gaining 267 points to close at 26,427 points, while the Hang Seng Tech Index increased by 1.48% [1] - Baidu Group-SW (09888) surged over 5% as its recent launch in Switzerland shifted core valuation logic towards AI support [1] - Bitcoin surpassed $115,000, increasing by 3.35% in a single day, leading to a rise in cryptocurrency-related stocks [1] Group 2 - Chongqing Bank (01963) increased by over 4%, reporting over 10% growth in both revenue and net profit for the first three quarters, with a proposed cash dividend of approximately 585 million yuan [2] - Meitu Inc. (01357) rose over 7%, achieving record high revenue for its three core apps in September, with expectations for a boost during the overseas holiday season [3] - Kangnex Optical (02276) gained over 5% as Alibaba's self-developed Quark AI glasses went on sale, with the company being the exclusive lens supplier [4] Group 3 - Boreton (01333) increased by 4%, as the electrification of mining moves into a market-driven phase, highlighting the performance advantages of its products [5] - Aux Electric (02580) rose over 7% after the board approved a three-year dividend payout plan, with stable domestic sales [6] - Tiangong International (00826) increased by over 6%, positioning itself in the scarce core materials sector, with significant growth potential in titanium alloys and nuclear fusion materials [7] Group 4 - Qiming Medical-B (02500) surged over 12% after completing all clinical enrollments for its CARDIOVALVE TTVR confirmatory clinical study [8] - GAC Group (02238) fell by 2.6%, reporting a loss of approximately 4.312 billion yuan for the first three quarters, marking a shift from profit to loss year-on-year [9] - Xiaomi Group-W (01810) declined by 2.7%, with Citigroup predicting its third-quarter performance may slightly underperform expectations [10]

每经AI快讯，启明医疗-B(02500.HK)涨超14%，截至发稿，涨14.01%，报2.93港元，成交额1077.73万港 元。 ...

公司表示，未来将持续推进包括Cardiovalve等多款自主研发的创新产品在全球范围内的临床研究、注册 申报和商业化布局，致力于早日实现"四瓣一体"结构性心脏瓣膜产品的完整布局，为全球更多患者提供 领先的瓣膜疾病解决方案，并进一步深化公司的国际化发展战略。 消息面上，启明医疗宣布，Cardiovalve经导管三尖瓣置换（TTVR）创新器械确证性临床研究已成功完 成全部150例患者临床入组。这是Cardiovalve在三尖瓣反流治疗领域的又一次重大研发进展，标志着其 在获取CE Mark的道路上迈出了关键里程碑。此外，TARGET研究的中期结果将于今年的伦敦心脏瓣膜 介入治疗会议（PCR London Valves 2025）上正式发布。 智通财经APP获悉，启明医疗-B(02500)涨超14%，截至发稿，涨14.01%，报2.93港元，成交额1077.73万 港元。 ...

Core Insights - The completion of the TARGET confirmatory clinical study with 150 patients marks a significant milestone for Cardiovalve in the treatment of tricuspid regurgitation, advancing its path towards CE MDR approval [1][2] - Cardiovalve is a self-developed transcatheter replacement product that can treat both mitral and tricuspid regurgitation, offering enhanced safety and applicability for approximately 95% of patients [1] Group 1 - The TARGET confirmatory clinical study is a prospective, multi-center, single-arm study conducted across over 30 cardiovascular centers in Europe (mainly Germany, Italy, Spain), the UK, and Canada [1] - Cardiovalve features a unique design with a maximum 55mm valve ring and a short valve frame that effectively reduces the risk of left ventricular outflow tract obstruction [1] Group 2 - The board believes that the completion of the clinical trial is a major milestone for the product's market entry and represents significant progress in innovative therapies for tricuspid regurgitation globally [2] - The company aims to leverage its established advantages in research, production, and commercialization in the global structural heart disease field to expedite the clinical registration and approval of innovative products like Cardiovalve [2]

Core Insights - The completion of the TARGET confirmatory clinical study with 150 patients marks a significant milestone for Cardiovalve in the treatment of tricuspid regurgitation, advancing its path towards CE MDR approval [1][2] - Cardiovalve is a self-developed transcatheter replacement product that can treat both mitral and tricuspid regurgitation, offering enhanced safety and suitability for approximately 95% of patients [1] - The company aims to leverage its established advantages in research, production, and commercialization in the global structural heart disease field to expedite the global clinical registration and approval of innovative products like Cardiovalve [2] Summary by Sections Clinical Study - The TARGET confirmatory clinical study is a prospective, multi-center, single-arm study conducted across over 30 cardiovascular centers in Europe (mainly Germany, Italy, Spain), the UK, and Canada, successfully enrolling 150 patients [1] - The study's completion is viewed as a major advancement in innovative therapies for tricuspid regurgitation on a global scale [2] Product Features - Cardiovalve features a unique design with a maximum 55mm valve ring, significantly improving treatment safety and reducing the risk of left ventricular outflow tract obstruction [1] - The product's operation is straightforward, requiring only three steps: positioning, anchoring, and releasing [1] Strategic Goals - The company is committed to advancing the global clinical registration development process for innovative products, including Cardiovalve, to benefit more patients and achieve its internationalization strategy [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 TARGET確證性臨床研究是針對三尖瓣反流的患者的一項前瞻性、多中心、單臂研 究，該 研 究 在 歐 洲（主 要 於 德 國、義 大 利、西 班 牙）、英 國 及 加 拿 大30餘家心血管中 心進行，共計招募150名患者。 Cardiovalve是一款自主研發、同時可用於治療二尖瓣反流和三尖瓣反流的經導管介 入置換產品。與同類產品相比，Cardiovalve經股靜脈的入路方式顯著提升了治療安 全 性，產 品 最 大55mm的大瓣環設計適用約95%的 患 者 群 體，同 時，其 獨 特 的 短 瓣 架設計可有效降低心室流出道梗阻風險。Cardiovalve操作簡單、安全、可複製性強， 只需定位、錨定、釋放三個步驟完成。 – 1 – 董 事 會 深 信，Cardiovalve完 成 歐 洲 確 證 性 臨 床 試 驗 ...

Core Insights - Southbound funds reduced their holdings in Qiming Medical-B (02500.HK) by 121,500 shares on October 15, 2025, marking a decrease of 0.22% [1] - Over the past five trading days, there has been a cumulative net reduction of 437,000 shares, while in the last twenty trading days, the total net reduction reached 1,048,000 shares [1] - As of now, southbound funds hold 53,968,600 shares of Qiming Medical-B, which accounts for 12.23% of the company's total issued ordinary shares [1] Company Overview - Qiming Medical is primarily engaged in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices for treating heart valve diseases [2] - The company's product line includes devices for aortic, pulmonary, mitral, and tricuspid valve interventions, as well as systems for treating hypertrophic cardiomyopathy and renal artery denervation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolic protection device [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02500 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 441,010,235 | RMB | | 1 RMB | | 441,010,235 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- ...